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OBJECTIVES The goal of this study was to learn more about the risk factors and short- and long-term
outcomes for primary angioplasty.
BACKGROUND Primary angioplasty (direct angioplasty without antecedent thrombolytic therapy) has been an
effective alternative to thrombolytic therapy for patients with acute myocardial infarction
(AMI). However, most reported studies have been compromised by small sample sizes and
short observation times.
METHODS New York’s coronary angioplasty registry was used to identify New York patients undergoing
angioplasty within 6 h of AMI between January 1, 1993 and December 31, 1996. Statistical
models were used to identify significant risk factors for in-patient and long-term survival and
to estimate long-term survival for all patients as well as various subsets of patients undergoing
primary angioplasty.
RESULTS The in-hospital mortality rate for all primary angioplasty patients was 5.81%. When patients
in preprocedural shock (who had a mortality rate of 45%) were excluded, the in-hospital
mortality rate dropped to 2.60%. Mortality rates for all primary angioplasty patients at one
year, two years and three years were 9.3%, 11.3% and 12.6%, respectively. Patients treated
with stent placement did not have significantly lower risk-adjusted in-patient or two-year
mortality rates.
CONCLUSIONS Primary angioplasty is a highly effective option for AMI. (J Am Coll Cardiol 2000;36:
1194–201) © 2000 by the American College of Cardiology
Numerous studies have been conducted to determine the
outcomes and benefits of primary percutaneous transluminal
coronary angioplasty (PTCA) in the treatment of acute
myocardial infarction (AMI), as well as its relative success in
comparison to thrombolytic therapy (1–12).
A meta-analysis of various randomized clinical trials that
was published in 1995 found a 44% reduction in six-week
mortality with primary PTCA relative to thrombolytic
therapy (odds ratio [OR] 5 0.56; 95% confidence interval,
0.35, 0.94) (13). However, most of the studies were based
on relatively small sample sizes. The authors of the meta-
analysis concluded that, although the combined results
suggest that PTCA may have superior outcomes to throm-
bolytic therapy, larger studies are needed to confirm the
results.
Although this study did not have access to patients
undergoing thrombolytic therapy without subsequent
PTCA, it did include a large number (n 5 2,291) of
patients who underwent PTCA within 6 h of AMI without
antecedent thrombolytic therapy (primary PTCA patients).
The purposes of this study were to identify significant
predictors of short-term (in-hospital) and long-term mor-
tality for primary PTCA, to determine three-year survival
for primary PTCA patients and to determine long-term
survival for subsets of primary PTCA patients (patients with
preprocedural shock and diabetes and patients undergoing
stent placement).
METHODS
Databases. In 1991, the New York State Department of
Health (the Department) and its Cardiac Advisory Com-
mittee (CAC) established a registry for coronary angioplasty
performed in the state, the Coronary Angioplasty Reporting
System (CARS). The CAC is a group of cardiac surgeons,
cardiologists, internists and patient advocates that advises
the Department on issues related to the quality of coronary
care, access to cardiac procedures and the prevention of
coronary heart disease.
The cardiac catheterization laboratories in the 33 hospi-
tals in which angioplasty is performed in New York are
responsible for coding the CARS forms to capture the
relevant information. When data fields are found to be
missing, hospitals are contacted by the Department and
asked to complete the missing information. Also, compre-
hensive audits of approximately half of the hospitals in each
registry are conducted on behalf of the Department each
year, and several hospitals have been asked to recode all or
part of their data as a result of the audits.
For each patient undergoing PTCA in New York State,
CARS contains demographic information; clinical risk fac-
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tors; patient, operator and hospital identifiers; complications
and discharge status from the hospital. An important data
element related to this study is whether the patient suffered
a recent AMI and the time period since the onset (coded as
0 to 6 h, 6 h to 24 h, number of days).
Another data base needed for the study was New York’s
vital statistics death file, which identifies all residents of the
state who have died each year. Since CARS and the death
file contain patient social security numbers, the two data-
bases were matched on social security numbers to obtain
deaths subsequent to discharge after the index hospitaliza-
tion.
Study population. Patients in the study consisted of all
New York State residents in all of the 33 hospitals who
underwent PTCA from 1993 to 1996 within 6 h after
experiencing an AMI and did not undergo thrombolytic
therapy within seven days before the PTCA. The study was
limited to residents of the state because the vital statistics
death file does not contain deaths for out-of-state residents,
so those patients could not be tracked for long-term
outcomes. In the interest of having the short-term (in-
hospital) and long-term samples identical, out-of-state pa-
tients were also excluded from the short-term analyses.
Although 12 h from the time of onset is the period most
commonly used in the randomized clinical trials for PTCA
versus thrombolysis, the 6-h time period for prior AMI was
used because the only times available in the Registry were
6 h, 24 h and number of days (up to 21 days). Six hours was
chosen rather than 24 h to ensure that the patient popula-
tion consisted of patients who underwent primary angio-
plasty for acute evolving infarction.
As yet, there is no registry for patients treated with
thrombolytic therapy in New York. Percutaneous translu-
minal coronary angioplasty patients who have undergone
thrombolytic therapy within seven days before the proce-
dure are identified in CARS, but no other time interval
between thrombolytic therapy and PTCA is available. Thus,
because we could not distinguish between patients who had
undergone thrombolytic therapy subsequent to the recent
AMI and patients who had undergone the therapy before
the AMI, all patients who underwent thrombolytic therapy
were not included in the study.
Study end points. Patients in the study were tracked to
determine if they died at any time during the study period,
and if so, how long they lived after undergoing the proce-
dure. Deaths during the same admission as the procedure
were identified using CARS, and deaths after discharge
following the procedure were identified using the death file.
For deaths after discharge, the time between the date of the
procedure and the date of death was noted.
Data analysis. The prevalence and in-hospital mortality
rate associated with each available determinant of mortality
were calculated. These risk factors included the number of
vessels diseased (with at least 70% stenosis) and lesion type
attempted; patient age, gender, race and ethnicity; a variety
of comorbidities and measures of the patient’s hemody-
namic state and ventricular function. The use of coronary
stents was also examined. All variables, including age and
ejection fraction, were treated as categorical variables, and
for some variables (ejection fraction, previous myocardial
infarction, vessels diseased, lesion type attempted, race),
more than two categories were defined. Chi-square tests
were used to identify significant differences in mortality
rates between categories.
A stepwise logistic regression model was developed using
the LOGISTIC procedure in SAS, Version 6.12 (SAS
Institute, Cary, North Carolina) in order to identify signif-
icant independent predictors of in-hospital mortality. The
binary dependent variable was discharge status from the
hospital after PTCA, with in-hospital mortality coded as a
“1.” Candidates for the independent variables included all
the demographic and clinical variables available in CARS,
including the use of stents. Variables were chosen for
inclusion in the model using a 0.05 level of significance. The
C statistic was used to measure the discrimination of the
model, and the Hosmer-Lemeshow statistic was used to
measure the model’s calibration. Another stepwise logistic
regression model was developed after excluding patients
with preprocedural shock. The same rules and candidate
covariates (except shock) were used in the second model as
in the original one.
Significant risk factors for long-term survival (up to three
years) were identified using stepwise Cox proportional
hazards models and the SAS procedure PHREG (Version
6.12). All demographic and clinical variables available in
CARS were used as candidate covariates, including the use
of stents.
RESULTS
Table 1 presents the prevalences and in-hospital mortality
rates for various risk factors associated with primary PTCA.
The total number of patients undergoing primary PTCA in
New York between 1993 and 1996 was 2,291. A total of 133
(5.81%) patients died in the hospital before discharge. The
1993 to 1996 risk-adjusted in-patient mortality rates were
6.57, 6.07, 5.03 and 5.97. None of these rates were
statistically different from the four-year rate.
Twenty-seven percent of the patients were at least 70
years old, and 5% were at least 80 years old. Thirty percent
were women, and 9% were noncaucasian. Nearly 8% were in
shock (systolic blood pressure less than 80 mm Hg or
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass graft
CAC 5 cardiac advisory committee
CARS 5 coronary angioplasty reporting system
CHF 5 congestive heart failure
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary angioplasty
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cardiac index less than 2.0 liters/min/m2), and another 15%
were hemodynamically unstable (required pharmacologic or
mechanical support to maintain blood pressure or output).
Four percent underwent previous open heart surgery, and
4% underwent a previous PTCA. Eleven percent of the
patients had congestive heart failure (CHF) during the same
admission, and 14% had diabetes. Most patients (63%) had
no more than one diseased vessel (stenosis $70%), and 1.5%
had left main disease. Twenty-one percent of the patients
underwent stent placement during the primary angioplasty.
However, the percentages in the respective years 1993 to
1996 were 0.3%, 3.3%, 19.8% and 42.1%.
The in-hospital mortality rate rose with increasing age
from 3% for patients under age 50 to 15.65% for patients
between 80 and 89, and the trend was significant (p ,
0.001, Table 1). Women had a significantly higher mortality
Table 1. Prevalence and In-patient Mortality Rates for Risk Factors Related to Primary








All Patients 2,291 100.00 5.81
Age:
,50 500 21.82 3.00
50–59 531 23.18 2.82
60–69 631 27.54 5.07
70–79 506 22.09 10.28 ,0.001
80–89 115 5.02 15.65
$90 8 0.35 12.50
Gender:
Female 686 29.94 9.04 ,0.001
Male 1,605 70.06 4.42
Hispanic ethnicity 112 4.89 9.82 0.092
Race:
White 2,092 91.31 5.83
Black 110 4.80 5.45 0.984
Other 89 3.88 5.62
Ejection fraction:
,30 119 5.19 26.05
30–39 201 8.77 7.96
$40 1,252 54.65 2.56 ,0.001
Missing 719 31.38 7.51
Stroke 87 3.80 19.54 ,0.001
Carotid/cerebrovascular disease 60 2.62 21.67 ,0.001
Aortoiliac disease 83 3.62 20.48 ,0.001
Femoral/popliteal disease 101 4.41 22.77 ,0.001
Hemodynamically unstable 334 14.58 7.78 0.100
Shock 173 7.55 45.09 ,0.001
ECG Evidence of LVH 124 5.41 11.29 0.015
Malignant ventricular 226 9.86 23.45 ,0.001
Arrhythmia
COPD 130 5.67 14.62 ,0.001
Diabetes requiring medication 323 14.10 12.38 ,0.001
Previous open heart surgery 88 3.84 13.64 0.004
CHF:
This admission 253 11.04 26.88
Before this admission 27 1.18 18.52 ,0.001
No CHF 2,011 87.78 2.98
Renal failure 42 1.83 30.95 ,0.001
Stent placement 484 21.13 4.55 0.228
Left main disease 35 1.53 40.00 ,0.001
Number of vessels diseased:
0 or 1 1,445 63.07 4.29
2 594 25.93 6.23 ,0.001
3 252 11.00 13.49
Lesion type attempted:
C 734 32.04 7.08
B 1,494 65.21 5.22 0.196
A 63 2.75 4.76
Previous PTCA(s) 102 4.45 10.78 0.046
CHF 5 congestive heart failure; COPD 5 chronic obstructive pulmonary disease; ECG 5 electrocardiograph; LVH 5 left
ventricular hypertrophy; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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rate than men (9.04% vs. 4.42%, p , 0.001) although
subsequent multivariate analyses demonstrated that the
difference is accounted for by their older ages. Hispanics had
higher than average mortality rates, but the differences were
not significant. Nearly all of the clinical risk factors available
in the database were significantly (bivariately) related to
in-hospital mortality. Exceptions were two intervention-
related variables: lesion type attempted and stent placement.
Risk factors with the highest mortality rates were shock
(45% mortality), left main disease (40%), renal failure
(creatinine .2.5 mg/dl or on dialysis, 31%), femoral/
popliteal disease (23%) and CHF during the same admis-
sion (27%). All were significantly related to mortality at the
0.001 level. There was also a progressive increase in mor-
tality rate with the number of vessels diseased (p , 0.001)
and with decreasing left ventricular ejection fraction.
Table 2 presents the significant risk factors for in-hospital
mortality after primary PTCA along with their logistic
regression coefficients, p values, OR and 95% confidence
intervals for the ORs. The risk factor with by far the highest
OR was shock (OR 5 23.62), followed by left main disease
(5.03) and hemodynamic instability (3.62). Other signifi-
cant risk factors were age, CHF during the same admission,
malignant ventricular arrhythmia, diabetes and stroke. Both
the C statistic (0.913) and the Hosmer-Lemeshow statistic
(p 5 0.73) indicated that the model fit was highly accept-
able.
Primary angioplasty patients in preprocedural shock had
a 45% in-hospital mortality rate compared with a 2.60%
mortality rate for primary angioplasty patients not in pre-
procedural shock. Thus, the mortality rate for shock patients
was 17 times as high as it was for other primary angioplasty
patients. In addition, 59% of all deaths among primary
angioplasty patients were among patients with preproce-
dural shock, despite the fact that these patients comprised
only 7.6% of all primary angioplasty patients.
Since preprocedural shock was such a dominant factor in
mortality of primary angioplasty patients and since many
previously reported randomized trials have excluded shock
patients, Table 3 presents the significant risk factors for
primary angioplasty patients who were not in shock. Risk
factors with the highest OR for in-hospital mortality were
CHF during the same admission (OR5 4.42), previous
PTCA (3.59) and malignant ventricular arrhythmia (3.52).
Age, carotid disease, hemodynamic instability and diabetes
were also significant. Again, the C statistic (0.847) and the
Hosmer-Lemeshow statistic (p 5 0.57) indicated excellent
model fit.
Table 4 presents the risk factors for long-term mortality
among patients who underwent primary angioplasty after
Table 2. Significant Multivariate Preprocedural Risk Factors for In-patient Mortality for Primary
Angioplasty: New York State, 1993 to 1996
n 5 2,291 Mortality Rate 5 5.81%
Risk Factor Coefficient p Value
OR
(95% CI for OR)
Age 0.0583 ,0.0001 1.060 (1.040, 1.081)
Hemodynamic instability 1.2872 ,0.0001 3.623 (2.024, 6.484)
Shock 3.1619 ,0.0001 23.615 (13.636, 40.898)
Congestive heart failure during
same admission
1.2245 ,0.0001 3.402 (2.133, 5.428)
Malignant ventricular arrhythmia 0.9652 0.0003 2.625 (1.564, 4.407)
Diabetes 0.7683 0.0036 2.156 (1.286, 3.615)
Left main disease 1.6144 0.0028 5.025 (1.743, 14.486)
Stroke 1.0267 0.0074 2.792 (1.317, 5.918)
CI 5 confidence interval; OR 5 odds ratio.
Intercept 5 28.4256; C 5 0.913; H-L statistic (p value) 5 0.728.
Table 3. Significant Multivariate Preprocedural Risk Factors for In-patient Mortality for Primary
Angioplasty (Shock Patients Excluded): New York State, 1993 to 1996
n 5 2,118 Mortality Rate 5 2.60%
Risk Factor Coefficient p Value
OR
(95% CI for OR)
Age 0.0745 ,0.0001 1.077 (1.047, 1.109)
Previous PTCA 1.2787 0.0097 3.592 (1.363, 9.468)
Congestive heart failure during
same admission
1.4864 ,0.0001 4.421 (2.365, 8.267)
Malignant ventricular arrythmia 1.2570 0.0005 3.515 (1.739, 7.105)
Carotid disease 1.1451 0.0246 3.143 (1.158, 8.528)
Hemodynamic instability 1.1781 ,0.0001 3.248 (1.777, 5.936)
Diabetes 0.8066 0.0200 2.240 (1.136, 4.419)
CI 5 confidence interval; OR 5 odds ratio; PTCA 5 percutaneous transluminal coronary angioplasty.
Intercept 5 29.7176; C 5 0.847; Hosmer-Lemeshow statistic (p value) 5 0.570.
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AMI. A comparison with Table 2 demonstrates that there
are several long-term risk factors that were not short-term
risk factors (female gender, ejection fraction, aortoiliac
disease, creatinine above 2.5, renal failure with dialysis and
two- or three-vessel disease). Risk factors with the highest
risk ratios were shock (risk ratio 5 4.66), dialysis (3.45) and
left main disease (2.88). It is also notable that stent
placement did not prove to yield significantly higher long-
term survival than other types of angioplasty, as evidenced
by its absence in the stepwise results.
Table 5 presents the rates for three adverse outcomes
(mortality, subsequent coronary artery bypass graft [CABG]
surgery, subsequent PTCA) for five time periods after
primary angioplasty (three months, six months, one year,
two years, three years). As indicated, the mortality rate rose
from 5.8% at three months to 12.6% at three years. A total
of 13.1% of primary angioplasty patients underwent CABG
surgery within three months of the index procedure, and
this percentage rose to 16.7% at one year, 17.9% at two years
and 19.4% at three years. The percentage of primary
angioplasty patients who underwent a subsequent PTCA
was initially much lower than the percentage undergoing
CABG surgery (5.9% at three months and 12.1% at one
year) but eventually approached the CABG surgery rate
(15.6% at two years and 17.6% at three years).
Table 6 presents the mortality rates for six time periods
(in-hospital, three months, six months, one year, two years
and three years) for all patients and for three subgroups of
patients having the following characteristics: shock, diabetes
and stent placement. Figure 1 provides graphs of the
survival curves for all primary angioplasty patients and for
the shock and diabetes patients.
As indicated in Table 6, diabetic patients undergoing
primary angioplasty had a 12.4% in-hospital mortality rate,
compared with the 5.8% mortality rate for all primary
angioplasty patients. This differential gradually increased as
the time after discharge from the hospital increased, to 8.3%
at one year after discharge and 8.4% two years after
discharge. The maximum differential of 10.2% (22.8% to
12.6%) occurred at three years after discharge.
Shock patients had an extremely high in-hospital mor-
tality rate of 45.1%. However, once they were discharged
alive from the hospital, their prognosis was similar to that of
the average patient who underwent primary angioplasty.
Between discharge from the hospital and three years later,
6.8% of all primary angioplasty patients died. For patients in
shock during the same time span, 4.0% died.
Patients undergoing stent placement could be followed
for only two years because most stent placements were
performed during or after 1994. The in-hospital mortality
for stent placement was 4.5% compared with 5.8% for all
patients. This 1.3% differential increased gradually as time
from discharge increased, to 2.5% at three months, 2.8% at
one year and a maximum of 3.1% (11.3% to 8.2%) at two
years.
DISCUSSION
Previous studies. Numerous studies have investigated the
effectiveness of primary angioplasty in the treatment of
Table 4. Significant Multivariate Preprocedural Risk Factors for Long-Term Mortality for
Primary Angioplasty: New York State, 1993 to 1996
Risk Factor Coefficient p Value
RR
(95% CI for RR)
Shock 1.5381 ,0.0001 4.656 (3.264, 6.641)
Dialysis 1.2373 0.0008 3.446 (1.670, 7.112)
Creatinine .2.5 0.6942 0.0401 2.002 (1.032, 3.885)
Left main disease 1.0578 0.0003 2.880 (1.616, 5.133)
Aortoiliac disease 0.7216 0.0004 2.058 (1.383, 3.061)
Congestive heart failure 0.7487 ,0.0001 2.114 (1.574, 2.839)
Malignant ventricular arrythmia 0.5515 0.0011 1.736 (1.247, 2.417)
Hemodynamic instability 0.6121 0.0005 1.844 (1.306, 2.605)
Ejection fraction ,20% 0.7316 0.0024 2.078 (1.297, 3.330)
Diabetes 0.4390 0.0044 1.551 (1.147, 2.098)
Female gender 0.3449 0.0106 1.412 (1.084, 1.839)
Age 0.0342 ,0.0001 1.035 (1.023, 1.047)
Two- or three-vessel disease 0.2907 0.0316 1.337 (1.026, 1.743)
Carotid disease 0.5883 0.0163 1.801 (1.114, 2.911)
CI 5 confidence interval; RR 5 risk ratio.
Table 5. Kaplan-Meier Adverse Outcome Rates for Primary Angioplasty New York State, 1993
to 1996 (%)
3 Months 6 Months 1 Year 2 Years 3 Years
Mortality 6.8 7.9 9.3 11.3 12.6
Subsequent CABG surgery 13.1 15.2 16.7 17.9 19.4
Subsequent PTCA 5.9 9.9 12.1 15.6 17.6
CABG 5 coronary artery bypass graft; PTCA 5 percutaneous transluminal coronary angioplasty.
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AMI. Most of these studies have been small, randomized
clinical trials that compared the relative effectiveness of
primary angioplasty and thrombolytic therapy on the basis
of short-term outcomes. Also, many of these randomized
clinical trials excluded high-risk patients and do not reflect
outcomes to be expected in patients treated in daily practice.
With regard to primary angioplasty mortality rates,
Grines et al. (1), using a 12-h period as the maximum time
between the onset of AMI and the performance of primary
angioplasty, reported a 2.6% in-hospital mortality rate for
195 patients not in shock who underwent primary angio-
plasty. The Global Use of Strategies To Open occluded
arteries (GUSTO) IIb Investigators, who used the same
12-h maximum period between AMI and angioplasty,
reported a 5.7% 30-day mortality rate among 565 primary
angioplasty patients, but no patients were in preprocedural
shock (2).
In a report from the Second National Registry of Myo-
cardial Infarction based on 4,939 patients who underwent
primary angioplasty, Tiefenbrunn et al. (3) reported a 5.2%
in-hospital mortality rate for nonshock patients and a 32%
in-hospital mortality rate for the 4.2% of patients who had
shock. Again, a 12-h maximum period between onset of
AMI and primary angioplasty was used. Garcia et al. (4)
reported a 2.8% in-hospital mortality rate for 109 patients
undergoing primary angioplasty and a 4.6% mortality rate at
six months. It does not appear that any of the patients were
in preprocedural shock.
Ribeiro et al. (8), who used a maximum 6-h period
between onset of the AMI and primary angioplasty, re-
ported a 6% in-hospital mortality rate for 50 patients
undergoing primary angioplasty. It is not clear whether any
of those patients were in preprocedural shock. Every et al.
(10), using a 6-h time frame between onset and performance
of the procedure, reported a 5.5% in-hospital mortality rate
for 1,272 primary angioplasty patients and a 12.1% mortal-
ity rate at three years. The incidence of preprocedural shock
in the study was 11.7%. In a study of 1,000 consecutive
primary angioplasty patients, O’Keefe et al. (11) reported a
7.8% in-hospital mortality rate. Patients in shock comprised
7.9% of the population and had a mortality rate of 44%;
patients not in shock had a mortality rate of 5%.
Summary of results. In this study, which used a maximum
6-h period between onset of the AMI and performance of
Figure 1. Three-year survival for primary angioplasty in New York State, 1993 to 1996: all patients and two subgroups (diabetes, shock).
Table 6. In-Hospital and Kaplan-Meier Mortality Rates for Primary Angioplasty for Selected
Risk Factors: New York State, 1993 to 1996
In-hospital 3 Months 6 Months 1 Year 2 Years 3 Years
All patients 5.8 6.8 7.9 9.3 11.3 12.6
Shock 45.1 45.2 45.2 46.8 47.4 49.1
Diabetes 12.4 14.0 16.8 17.6 19.7 22.8
Stent placement 4.5 5.3 5.6 6.5 8.2 NA
NA 5 not available.
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primary angioplasty, the in-hospital mortality rate was
5.81%. A total of 7.6% of the patients were in preprocedural
shock, and the in-hospital mortality rate for those patients
was 45%. The in-hospital mortality rate for patients not in
preprocedural shock was 2.60%. For all primary angioplasty
patients in the study, the mortality rate was 9.3% at one
year, 11.3% at two years and 12.6% at three years.
In summary, in the previous studies, the range of in-
hospital mortality rates for primary angioplasty patients not
in shock varied from 2.6% to 5.2%. The in-hospital rate in
our study was 2.6%. The two in-hospital mortality rates that
were reported in other studies for shock patients undergoing
primary angioplasty were 32% and 44%, compared with a
45% mortality rate in our study. The overall in-hospital
mortality rates for primary angioplasty in the previously
reported studies ranged from 5.7% to 7.8%; in our study we
found a 5.81% mortality rate for all patients. The only study
in the literature that reported a three-year mortality rate
found a rate slightly lower than the rate found in our study
(12.1% vs. 12.6%) (10).
Thus, the rates reported in our study are, for the most part,
similar to those reported by other studies in the literature.
Furthermore, the mortality rates reported in this study for
primary angioplasty are lower than the rates reported for
thrombolytic therapy in recent studies. For example, the
National Registry of Myocardial Infarction-2 trial reported a
52% in-hospital mortality rate for patients in shock and a 5.4%
mortality rate for patients not in shock (our corresponding rates
were 45% and 2.6%, with a 5.81% overall rate) (3). The
Primary Angioplasty in Myocardial Infarction trial reported a
6.5% in-hospital mortality rate (1). An obvious caveat is that
our study did not randomize patients to primary angioplasty, so
a selection bias may have existed.
Caveats. There are differences between this study and most
other studies reported in the literature. First, this was not a
randomized clinical trial, and, in fact, no patients undergo-
ing thrombolytic therapy as an alternative intervention for
AMI were in the study. No such registry exists for patients
undergoing thrombolytic therapy in New York. Although
patients who underwent thrombolytic therapy before pri-
mary angioplasty are included in the Registry, this group
was excluded from the study because it was impossible to
determine from the Registry whether they had undergone
thrombolytic therapy before or after the onset of the recent
AMI. An advantage of our study is that, to the best of our
knowledge, this is the first statewide population-based study
of primary angioplasty. Except for patients undergoing prior
thrombolytic therapy, the study includes all patients who
underwent the procedure in New York State between 1993
and 1996.
The maximum allowable time frame used in this study for
the period between onset of AMI and the performance of
primary angioplasty was 6 h. Most studies in the literature
use a 12-h maximum onset period and some use the 6 h
time frame. There was not an option to use a 12-h period in
this study because the only time periods less than 24-h that
are recorded in the Registry are 0 to 6 h and 6 to 24 h. The
6-h time period was chosen rather than the 24 h time period
to ensure that the patient population consisted of patients
who underwent primary angioplasty for acute evolving
infarction.
Another limitation of the study was that there was no
information in the Registry that indicated whether patients
undergoing primary angioplasty were ineligible for thrombo-
lytic therapy. It should be noted that a contraindication for
thrombolytic therapy is now a data element in the Registry.
An important ancillary finding of the study is that shock
patients who were discharged alive from the hospital after
primary angioplasty had lower three-year mortality rates
than other primary angioplasty patients (4% vs. 6.8%,
respectively). A caveat is that there were only 95 shock
patients discharged alive from the hospital (out of 173
admissions). Another important finding was that patients
treated with coronary stent placements did not have superior
short-term or long-term outcomes compared with patients
not receiving stent placements for primary angioplasty.
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